SCHEMBL8176397

SCHEMBL8176397

COC(=O)c1ccc(-n2cncn2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP3A4 P08684 1/20 0.52
POLB P06746 2/20 0.49
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 2/20 0.47
HSP90AA1 P07900 1/20 0.47
MYC P01106 1/20 0.46
KDM4E B2RXH2 4/20 0.45
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
F9 P00740 2/20 0.43
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CYP2D6 P10635 1/20 0.40
GRM2 Q14416 1/20 0.39
NOTUM Q6P988 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8168631 0.85 F9 (0.49) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL8167427 0.84 SMN1; SMN2 (0.47) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL8176394 0.83 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL8175262 0.82 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL63446 0.81 CYP1A2 (0.62) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL8175811 0.80 HSP90AA1 (0.39) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL20556372 0.78 MAPT (0.52) MAPTMYCKDM4EALOX15TSHR
SCHEMBL8490965 0.76 F9 (0.42) MAPTSMN1; SMN2HTTHSP90AA1KDM4E
SCHEMBL5869031 0.76 TP53 (0.64) CYP1A2CYP2C9CYP2C19CYP3A4POLB
SCHEMBL20556408 0.76 MAPT (0.44) POLBMAPTMYCKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834183-B2 Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound FUJIFILM FINECHEMICALS CO., LTD (JP) 2010-11-16 US disclosed
US-7834183-B2 Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound FUJIFILM FINECHEMICALS CO., LTD (JP) 2010-11-16 US disclosed
US-20070135633-A1 Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-06-14 US disclosed
US-20070135633-A1 Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-06-14 US disclosed
EP-1795529-A2 Process for producing N-(Hetero)Aryl-substituted nitrogen-containing heteroaryl compound FUJIFILM FINECHEMICALS CO., LTD. (JP) 2007-06-13 EP disclosed
US-6048984-A HERBICIDES AND ANTIGROWTH AGENTS RHONE-POULENC AGRICULTURE LIMITED (GB) 2000-04-11 US disclosed
US-5977376-A Herbicidal 2-benzoylcyclohexane-1,3-diones and related compounds RHONE-POULENC AGRICULTURE LIMITED (GB) 1999-11-02 US disclosed
WO-1999003856-A1 4-BENZOYL-ISOXAZOLE- AND -PYRAZOLE DERIVATIVES AND 2-CYANO 1,3-DIONE DERIVATIVES AS HERBICIDES RHONE-POULENC AGRICULTURE LIMITED (GB) 1999-01-28 WO disclosed
WO-1999003845-A1 2-BENZOYLCYCLOHEXANE-1,3-DIONE DERIVATIVES AS HERBICIDES AND INTERMEDIATES RHONE-POULENC AGRICULTURE LIMITED (GB) 1999-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135633-A1 Process for producing N-(hetero)aryl-substituted nitrogen-containing heteroaryl compound PARG, PARN, ASNS CYP1A2 215/4885CYP2C9 256/4885CYP2C19 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.